Clinical Report: Efficacy and Safety of PD-1 Inhibitors in RM-NPC

Overview

This systematic review and meta-analysis evaluated the efficacy, long-term survival, and safety of various PD-1 inhibitors combined with chemotherapy in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).

Background

Recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) presents a significant clinical challenge due to its poor prognosis and limited treatment options. The introduction of PD-1 inhibitors has changed treatment approaches, yet comparative efficacy and safety data among different PD-1 inhibitors remain insufficient.

Data Highlights

Key Findings

• The pooled objective response rate (ORR) was 64% and disease control rate (DCR) was 94% across all regimens.
• Toripalimab-based regimens achieved the highest ORR and longest median PFS of 21.4 months.
• Tislelizumab plus chemotherapy yielded the most favorable median OS of 45.3 months.
• Camrelizumab plus chemotherapy showed a median OS of 34.5 months.
• The pooled incidence of grade ≥3 treatment-related adverse events (TRAEs) was 13%, with comparable safety profiles across all PD-1 inhibitors.

Clinical Implications

The findings suggest that PD-1 inhibitors combined with chemotherapy can provide substantial efficacy and long-term survival benefits in RM-NPC. Clinicians may consider individualizing PD-1 inhibitor selection based on the observed therapeutic effects of toripalimab, tislelizumab, and camrelizumab.

Conclusion

This systematic review and meta-analysis confirm the efficacy and safety of PD-1 inhibitors in RM-NPC, highlighting the importance of agent selection in clinical practice.

Related Resources & Content

1. Conexiant, PD-1/PD-L1 Inhibitors May Improve Survival in NPC
2. The ASCO Post, Metabolic Subtypes of Nasopharyngeal Carcinoma and Response to Treatment
3. The ASCO Post, Role of Chemotherapy in Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Radiotherapy
4. NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
5. Frontiers in Immunology — PD-1/PD-L1 inhibitors plus chemotherapy as first-line therapy for advanced or metastatic endometrial cancer: a systematic review and meta-analysis of randomized controlled trials
6. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial
7. NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025 - PubMed